RDUS Radius Health Inc.

Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022

Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022

BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a business update.

Conference Call Information:

Domestic Dial-In Number: 1 (866) 323-7965

International Dial-In Number: 1 (346) 406-0961

Conference ID: 5844208

Webcast Link:

A replay of the conference call will be available on May 5th at 11:30 a.m. ET. A live audio webcast of the call will be archived on the Company's website for 12 months. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 5844208. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, . The full text of the announcement and financial results will also be available on the Company’s website.

About Radius

Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Our team works collaboratively and relentlessly to advance our therapies; all with the goal of improving the lives of patients, their families, and their caregivers. The Radius portfolio consists of commercial and clinical development assets, including early to late-stage drug candidates. Find out more at

Investor & Media Relations Contact:

Ethan Holdaway

Email: 

Phone: (617) 583-2017



EN
25/04/2022

Underlying

RDUSRadius Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Radius Health Inc.

Free Trial
RDUS Radius Health ...

Radius Recycling Inc: 1 director

A director at Radius Recycling Inc sold 17,675 shares at 17.080USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

RDUS RADIUS HEALTH INC.
11/01/24 November 1, 2024 1 EN
 PRESS RELEASE
Free
RDUS Radius Health ...

Gurnet Point Capital and Patient Square Capital Complete Their Acquisi...

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of...

August 15, 2022 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 44.79
XNCR XENCOR INC.
VCYT VERACYTE INC ... (+33)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

XNCR XENCOR INC.
VCYT VERACYTE INC
RDUS RADIUS HEALTH INC.
FOLD AMICUS THERAPEUTICS INC.
CYTK CYTOKINETICS INCORPORATED
AVXL ANAVEX LIFE SCIENCES
AGIO AGIOS PHARMACEUTICALS INC.
NTLA INTELLIA THERAPEUTICS INC.
CYRX CRYOPORT INC.
DH DELICE HOLDING
FNKO FUNKO CLASS A
RCKT ROCKET PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
ALEC ALECTOR
RAD RITE AID CORPORATION
TMDX TRANSMEDICS GROUP
CHWY CHEWY INC. CLASS A
HCAT HEALTH CATALYST
RAPT RAPT THERAPEUTICS
ALT ALTIMMUNE INC
AVEO AVEO PHARMACEUTICALS INC.
SPT SPROUT SOCIAL
FSTX F-STAR THERAPEUTICS INC
MASS 908 DEVICES
DAWN DAY ONE BIOPHARMACEUTICALS INC
GTLB GITLAB INC
AGL AGILON HEALTH INC
VERV VERVE THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
BRZE BRAZE INC
RXRX RECURSION PHARMACEUTICALS INC
JANX JANUX THERAPEUTICS INC
WEBR WEBER INC
06/24/22 June 24, 2022 1 EN
 PRESS RELEASE
Free
RDUS Radius Health ...

Radius Health Announces Agreement to be Acquired by Gurnet Point Capit...

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of $11.00, including $10.00 cash paid at closing and potential $1.00 CVRRepresents total transaction consideration of up to approximately $890 million BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced tha...

June 23, 2022 1 EN
 PRESS RELEASE
Free
RDUS Radius Health ...

Menarini Group and Radius Health Submit New Drug Application to the U....

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, and currently only, investigational oral SERD with positive topline resultsAdditional data presented at SABCS (December 2021) and ASCO (June 2022)Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON, June ...

June 22, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch